SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is experiencing a surge driven by significant momentum in the memory sector, coupled with optimism surrounding its defense-related contracts and role in AI infrastructure. Investors are actively discussing the potential for a gamma squeeze fueled by high call option interest and a low float, despite polarized community debate regarding recent legal headwinds and the stock's valuation.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently a focal point for investors as it nears multi-year lows, with market participants weighing a polarizing mix of rumors regarding a potential Yeezy brand partnership against ongoing concerns over market share losses and litigation. While the community remains deeply divided, discussions are dominated by the stock's oversold technical setup, high-profile insider buying from executives like Tim Cook, and speculative anticipation for a long-term turnaround driven by upcoming global sporting events.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing intense backlash following a lawsuit from the Texas Attorney General alleging the platform illegally tracks and collects data on children to fuel addictive algorithms. While the stock faces downward pressure amid broader market rotation into semiconductors, the community remains deeply polarized between long-term investors pointing to strong fundamental cash flow and vocal detractors calling for boycotts and management changes over these privacy concerns.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing a volatile rally driven by reports that Elon Musk will join a U.S. delegation to China, sparking intense speculation regarding potential FSD approvals and geopolitical impact on its supply chain. While bulls are leveraging the news and AI-focused momentum to drive the stock higher, community members remain deeply divided, with many debating the sustainability of current valuations and the long-term feasibility of the Optimus robot program amidst shifting trade dynamics.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is drawing significant investor interest as traders debate whether current volatility represents a cooling phase or the setup for a major breakout driven by industrial demand and supply chain constraints. The community remains heavily divided, with intense discussion surrounding the asset's correlation to oil and the dollar, prompting aggressive positioning in both short-term derivatives and long-term accumulation plays.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as a major beneficiary of the AI-driven memory supercycle, with institutional price target hikes and potential supply tightness due to labor tensions at Samsung fueling significant momentum. The community is actively debating whether the stock is in a sustainable structural repricing phase or a speculative bubble, with many traders focused on its rapid move toward a trillion-dollar valuation.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing heightened trading activity as the community closely monitors the legislative progression of the CLARITY Act, which remains a primary catalyst for potential valuation shifts. Investors are actively debating the company's long-term infrastructure role, balancing optimism over stablecoin adoption against concerns regarding regulatory outcomes and earnings performance.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing significant volatility and intense community discussion following the announcement of a $2 billion convertible note offering to fund its AI infrastructure expansion and partnership with NVIDIA. While some investors express concern over potential dilution, bulls remain highly optimistic, citing the company's status as a critical AI infrastructure provider and strong institutional demand for its shares.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant attention as investors await the upcoming Phase 3 VELA-1 and VELA-2 dataset, which is viewed as a crucial catalyst to validate sonelokimab as a best-in-class treatment for inflammatory skin diseases. Community sentiment remains focused on the potential for institutional accumulation and long-term value, despite ongoing volatility and concerns regarding short interest and the timing of clinical trial readouts.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is seeing significant trading activity as investors react to increased institutional buying and a direct correlation with Bitcoin's recent price appreciation. The community is actively debating the company's Bitcoin-centric business model and potential for future upside, with many bulls highlighting the stock as a leveraged proxy for long-term cryptocurrency gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Joanne Donovan Sells 50,000 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 50,000 shares of the firm's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the transaction, the...

Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells $163,646.70 in Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 5,230 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $31.29, for a total value of $163,646.70. Following the sale, the chief marketing officer owned...

<ul class="summary-bullets"><li>Several secondary measures, including heart function and symptom severity, also improved meaningfully.</li><li>Truist raised its price target on Cytokinetics to $106 from $92 following the trial update and maintained a ‘Buy’ rating, according to The Fly.</li><li>Stifel said CYTK’s phase 3 trial outcome proves the class of drugs works, though Edgewise’s EDG-7500 is ‘best-positioned.’</li></ul>Shares of Cytokinetics (CYTK) soared more than 16% on Tuesday, climbing to its highest level in over two years, as investor enthusiasm surged following strong late-stage trial results for a treatment targeting a serious heart condition linked to sudden cardiac arrest.Truist raised its price target on Cytokinetics to $106 from $92 following the trial update and maintained a ‘Buy’ rating, according to The Fly.<h2 class="st-heading-2">CYTK’s Aficamten Meets Primary Endpoints</h2>The company said its drug Aficamten for patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM) met both primary endpoints, showing significant improvements in health-related quality of life and exercise capacity compared with placebo at 36 weeks.Several secondary measures, including heart function and symptom severity, also improved meaningfully. The treatment was generally well tolerated, with no new safety concerns identified.Completion rates were similar between the Aficamten and placebo groups, though reduced heart function was seen in 10% of patients on the drug.<h2 class="st-heading-2">CYTK Vs EWTX: Analysts’ View</h2>Raymond James said Cytokinetics’ positive Phase 3 result for Aficamten bodes well for Edgewise Therapeutics (EWTX). The firm said Edgewise’s EDG-7500 therapy may be even better suited to target the underlying heart condition and considers it one of the most compelling assets currently in development for HCM. The firm has a ‘Strong Buy’ rating on Edgewise.Stifel also said that CYTK’s phase 3 trial outcome could be a positive setup for Edgewise, supporting the view that this class of drugs works, though EDG-7500 is “best-positioned”. However, the firm cautioned that questions around safety and how these drugs compare to each other will “take time to answer in the backdrop of an increasingly competitive landscape.”&nbsp;Stifel has a ‘Buy’ rating on Cytokinetics and a ‘Hold’ on Edgewise. <a href="https://stocktwits.com/symbol/EWTX">EWTX shares</a> gained 18% to their highest in over five years.<h2 class="st-heading-2">Retail Sees Strong Upside In CYTK’s Stock Price</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CYTK">CYTK</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes. Sentiment for EWTX was ‘neutral.’One user said CYTK stock’s upside is “insane and mostly derisked.”<stembedurl>https://stocktwits.com/forprofit12/message/652283716</stembedurl>Another user said the FDA’s approval for CYTK’s therapy is “almost guaranteed.”<stembedurl>https://stocktwits.com/forprofit12/message/652278320</stembedurl>Both stocks have seen strong growth so far this year. While CYTK has added around 22%, EWTX gains are nearly double at 42%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/grrr-stock-gorilla-thailand-data-center-deal-1.5-billion-revenue-potential/cZQDcbGRe9Q">GRRR Stock In Focus Again As Asian Expansion Leads To Thailand Data Center Deal – Retail Buzzes On Solid Revenue Potential</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cytokinetics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

The company said Aficamten for patients with symptomatic non-obstructive hypertrophic cardiomyopathy met both primary endpoints.

Equity

Edgewise Therapeutics (NASDAQ:EWTX) Sets New 52-Week High  - Should You Buy?

Edgewise Therapeutics (NASDAQ:EWTX) Hits New 1-Year High - Time to Buy...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Analysts

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat.com...

Edgewise Therapeutics (EWTX) to Release Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Moody Aldrich Partners LLC Has $1.07 Million Holdings in Edgewise Therapeutics, Inc. $EWTX

Moody Aldrich Partners LLC cut its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 48.0% in the fourth quarter, according to the company in its most recent filing with the...

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Here's What Happened

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Should You Buy...

Edgewise Therapeutics, Inc. $EWTX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 104.8% during the 4th quarter, according to its most recent 13F...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Current Price	$34.34
Prev Close	$35.32
Open	$35.70
Dividend Yield	0.00%
50-Day Moving Average	$31.60
Beta	1.39
Avg. Volume	990,254.29
PE Ratio	-21.27

52-Week High	$39.96
52-Week Low	$12.15
Market Capitalization	$3.8B
EPS (Annual)	-$1.63
Price to Book	7.70
Revenue Per Employee	$0.00

EWTX
Edgewise Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EWTX News

EWTXEdgewise Therapeutics Inc